MicroRNA-22 Promotes Apoptosis of Human Aortic Smooth Muscle Cells by Targeting P38mapk Alpha in Vascular Remodeling of Aortic Dissection
Zaiping Jing,Xiao Yu,Yudong Sun,Xiang Ma,Chen Wang,Lei Zhang,Jiannan Wang,Guokun Wang,Wen Tian,Zhiqing Zhao,Qing Jing,Jian Zhou
DOI: https://doi.org/10.2139/ssrn.3453321
2019-01-01
Abstract:Background: Post-transcriptional mechanisms, including microRNA-mediated inhibition of gene expression, participates in vascular remodeling by modulating the biological functions of VSMCs.Methods: We explored the miR-22 expression in aortic tissues from normal and thoracic aortic dissection patients respectively. In addition, we noticed that the apoptosis of VSMCs was regulated by miR-22 in vitro, and in vivo aortic dissection models.Findings: The miR-22 expression of aortic tissues in AD patients is lower than NA patients (P < 0.05). Apoptosis of VSMCs accelerates in human aorta with aortic dissection. In the meanwhile, downregulation of miR-22 increases the apoptosis of VSMCs, vice versa. Bioinformatics and luciferase analyses reveals that p38MAPKα is a novel target of miR-22. Inhibiting p38MAPKα expression could reverse the apoptosis of VSMCs, which is induced by downregulation of miR-22. Moreover, p38MAPKα expression is significantly positively correlated with the rate of apoptosis of VSMCs in aortic dissection tissues. Knockdown of miR-22 in a murine AD model significantly promotes the incidence rate of aortic dissection by enhancing the degradation of elastin and collagen. Finally, in-situ TUNEL staining shows that downregulation of miR-22 increases the apoptosis of VSMCs in mice aorta as well as p38MAPKα expression.Interpretation: Our study underscores the importance of vascular remodeling and VSMC function in controlling the development of aortic dissection.Funding Statement: This study was financed by the National Natural Science Foundation of China (81570425 and 91739110).Declaration of Interests: The authors declare they have no conflicts of interest.Ethics Approval Statement: All animal experiments were performed in accordance with the animal protocols approved by the Institutional Animal Care and Use Committee of Anti-Cancer Biotech (Beijing, China). Prior written informed consents from all patients inaccordance with the Declaration of Helsinki and the approval from the Ethics Committee of The Second Military Medical University Changhai Hospital were obtained.